Search

Search Results

1. State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV

   Background

   Two decades ago, stage IV non-small-cell lung cancer (NSCLC) was associated with a poor median overall survival (mOS) of 7–9 months...

   Sophie Heinzen, Henning Reis, ... Jan Stratmann in Die Onkologie

   Article 25 October 2022
   

2. State of the Art: nicht onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV

   Background

   In Germany, lung cancer is the third most common malignant tumor in women and ranks second in number of cancer-related deaths, while in men...

   Svenja Neise, Martin Reck in Die Onkologie

   Article 24 October 2022
   

3. Konzepte beim oligometastasierten Lungenkarzinom

   Background

   In metastatic non-small-cell lung cancer, palliative systemic therapy is the mainstay of therapy. The subgroup oligometastasis defines...

   Joachim Pfannschmidt, Matthias Guckenberger, Wilfried E. E. Eberhardt in Wiener klinisches Magazin

   Article 25 April 2023
   

4. Konzepte beim oligometastasierten Lungenkarzinom

   Background

   In metastatic non-small-cell lung cancer, palliative systemic therapy is the mainstay of therapy. The subgroup oligometastasis defines...

   J. Pfannschmidt, M. Guckenberger, W. E. E. Eberhardt in Die Onkologie

   Article 04 November 2022
   

5. Chancen und Grenzen der stereotaktisch fraktionierten Hochpräzisionsbestrahlung beim nichtkleinzelligen Lungenkarzinom im Stadium I/II

   Background

   Fractionated stereotactic body radiotherapy (SBRT) can achieve excellent tumor control with good toxicity profiles and maintained quality...

   Sonja Adebahr, Denise Bernhardt in Die Onkologie

   Article 07 November 2022
   

6. Oligometastasiertes nichtkleinzelliges Lungenkarzinom: lokaltherapeutische Optionen zur Behandlung von Lungen- und Nebennierenmetastasen

   Background

   Limited metastatic spread of non-small-cell lung cancer (NSCLC) has been defined as a distinct cancer stage in the 8th edition of the TNM...

   Matthias Guckenberger, Kuno Lehmann, Isabelle Opitz in Der Onkologe

   Article 16 July 2020
   

7. Immuncheckpointinhibitoren beim Lungenkarzinom

   Immune checkpoint inhibitors (ICI) have emerged as an important treatment strategy in lung cancer in recent years. Implementation and approval status...

   S. Koleczko, J. Wolf in Der Internist

   Article 27 May 2020
   

8. Flächendeckende onkologische Qualitätssicherung durch Landeskrebsregister am Beispiel des Lungen- und Zervixkarzinoms

   Introduction

   With the establishment of nationwide cancer registration in Germany based on the Act for the Implementation of the Early Detection of...

   Mike Klora, Petra Neuser, ... Alexander Katalinic in Die Onkologie

   Article 28 February 2024
   

9. Lokal fortgeschrittenes nichtkleinzelliges Lungenkarzinom: Radioimmuntherapie als neuer Standard?

   Background

   Concurrent radiochemotherapy has been established as a treatment standard for patients with inoperable non-small cell lung cancer (NSCLC)...

   Alexander Fabian, Justus Domschikowski, ... David Krug in Der Pneumologe

   Article 08 July 2019
   

10. Nichtkleinzelliges Lungenkarzinom – Staging nach TNM und Therapieprinzipien

    R. M. Huber in Der Onkologe

    Article 19 November 2018
    

11. Neue Substanzen und Kombinationen für die Therapie von morgen

    Friederike Klein in InFo Hämatologie + Onkologie

    Article 14 December 2023
    

12. NSCLC zielgerichtet therapieren

    Redaktion Facharztmagazine in InFo Hämatologie + Onkologie

    Article 19 April 2024
    

13. Pneumologie meets Onkologie

    Lung cancer is common and associated with a high mortality. After major therapeutic advances in the palliative situation of non-small cell lung...

    Matthias Raspe, Nikolaj Frost in Zeitschrift für Pneumologie

    Article 20 December 2022

14. Trouble um ersten KRAS-Inhibitor

    Moritz Borchers in InFo Hämatologie + Onkologie

    Article 21 June 2024

15. Epidemiologie des nichtkleinzelligen Lungenkarzinoms in Deutschland – ein Update

    Katharina Emrich, Klaus Kraywinkel in Zeitschrift für Pneumologie

    Article 07 August 2023
    

16. Neue Daten zu Dato-DXd

    Redaktion Facharztmagazine in InFo Hämatologie + Onkologie

    Article 20 November 2023

17. CUP-Syndrom – die neue ESMO-Leitlinie

    Background

    The European Society of Medical Oncology (ESMO) recently published extensively revised guidelines on cancer of unknown primary (CUP). The...

    Tilmann Bochtler, Maria Pouyiourou, Alwin Krämer in best practice onkologie

    Article 22 May 2023
    

18. Resektion im NSCLC-Stadium IA: Wie viel reicht aus?

    Adrian Gillissen in InFo Hämatologie + Onkologie

    Article 25 July 2023
    

19. Immuntherapie des nichtkleinzelligen Lungenkarzinoms (NSCLC)

    Within a few years the introduction of immune checkpoint inhibitors (ICI) fundamentally changed the treatment landscape of patients with metastatic...

    Nikolaj Frost, Martin Reck in Die Innere Medizin

    Article 15 June 2022
    

20. CUP-Syndrom – die neue ESMO-Leitlinie

    Background

    The European Society of Medical Oncology (ESMO) recently published extensively revised guidelines on cancer of unknown primary (CUP). The...

    Tilmann Bochtler, Maria Pouyiourou, Alwin Krämer in Die Radiologie

    Article 17 March 2023